Insulin independence for LCT
Tuesday, 07 April, 2009
New Zealand’s Living Cell Technologies has reported that a patient with type 1 diabetes is currently insulin independent following treatments in an early stage trial.
LCT is running the safety and dosing trial in Moscow. Seven patients have received Diabecell implants at a low or medium dose.
Diabecell is a microencapsulated product containing insulin-producing porcine islet cells. In the female patient, live porcine cells in their capsules have been found in the abdomen and porcine insulin was detected in her blood.
The 37-year-old had been on daily insulin injections for 15 years. She is now maintaining good blood glucose control without injections, LCT said.
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
Perioperative trial offers insights into brain cancer treatment
Victorian brain cancer researchers have used an innovative process to learn how a new drug...
